IL295744A - glp-1r and gcgr agonists, formulations and methods of use - Google Patents

glp-1r and gcgr agonists, formulations and methods of use

Info

Publication number
IL295744A
IL295744A IL295744A IL29574422A IL295744A IL 295744 A IL295744 A IL 295744A IL 295744 A IL295744 A IL 295744A IL 29574422 A IL29574422 A IL 29574422A IL 295744 A IL295744 A IL 295744A
Authority
IL
Israel
Prior art keywords
dose
pharmaceutical dosage
mammal
optionally
weeks
Prior art date
Application number
IL295744A
Other languages
English (en)
Hebrew (he)
Original Assignee
Spitfire Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spitfire Pharma Llc filed Critical Spitfire Pharma Llc
Publication of IL295744A publication Critical patent/IL295744A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL295744A 2020-02-21 2021-02-21 glp-1r and gcgr agonists, formulations and methods of use IL295744A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062980093P 2020-02-21 2020-02-21
US202063122108P 2020-12-07 2020-12-07
US202163133540P 2021-01-04 2021-01-04
PCT/US2021/018947 WO2021168386A1 (en) 2020-02-21 2021-02-21 Glp-1r and gcgr agonists, formulations, and methods of use

Publications (1)

Publication Number Publication Date
IL295744A true IL295744A (en) 2022-10-01

Family

ID=77391258

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295744A IL295744A (en) 2020-02-21 2021-02-21 glp-1r and gcgr agonists, formulations and methods of use

Country Status (11)

Country Link
US (2) US20210290732A1 (cg-RX-API-DMAC10.html)
EP (1) EP4106796A4 (cg-RX-API-DMAC10.html)
JP (2) JP7752619B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220143923A (cg-RX-API-DMAC10.html)
CN (1) CN115427065A (cg-RX-API-DMAC10.html)
AU (1) AU2021224246A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022016470A2 (cg-RX-API-DMAC10.html)
CA (1) CA3168001A1 (cg-RX-API-DMAC10.html)
IL (1) IL295744A (cg-RX-API-DMAC10.html)
MX (1) MX2022010320A (cg-RX-API-DMAC10.html)
WO (1) WO2021168386A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4286400A3 (en) * 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2014081872A1 (en) * 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
US20230317230A1 (en) * 2019-05-02 2023-10-05 Closed Loop Medicine Ltd. Method for treating obesity
CN117202924A (zh) * 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
US20240148879A1 (en) * 2021-02-21 2024-05-09 Spitfire Pharma Llc Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use
KR20240118786A (ko) * 2021-12-01 2024-08-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Glp-1 및 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도
KR20250067161A (ko) * 2022-09-14 2025-05-14 스핏파이어 파마, 엘엘씨 Glp-1r 및 gcgr 효능제를 사용하여 지방간 질환을 앓는 피험체에서 체중을 감소시키기 위한 치료 요법 및 방법
WO2024098071A1 (en) * 2022-11-05 2024-05-10 Spitfire Pharma Llc Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280814A1 (en) 2004-09-17 2008-11-13 Novo Nordisk A/S Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
EP4286400A3 (en) * 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2014081872A1 (en) * 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
EP2922877B1 (en) * 2012-11-20 2018-09-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
BR112015025464A2 (pt) * 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
CN117582516A (zh) * 2014-05-28 2024-02-23 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
PE20170471A1 (es) 2014-06-13 2017-05-14 Santa Maria Biotherapeutics Inc Polipeptidos receptores formulados y metodos relacionados
JP2017517549A (ja) * 2014-06-13 2017-06-29 サノフイ 活性薬剤成分のナノカプセル製剤
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
FI3322437T3 (fi) * 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
AU2019205905B2 (en) * 2018-01-03 2024-12-12 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of NASH and other disorders

Also Published As

Publication number Publication date
AU2021224246A1 (en) 2022-09-15
JP2023514992A (ja) 2023-04-12
CN115427065A (zh) 2022-12-02
KR20220143923A (ko) 2022-10-25
EP4106796A1 (en) 2022-12-28
EP4106796A4 (en) 2024-04-17
WO2021168386A1 (en) 2021-08-26
CA3168001A1 (en) 2021-08-26
JP2026021305A (ja) 2026-02-10
US20210290732A1 (en) 2021-09-23
BR112022016470A2 (pt) 2022-11-22
US20250262280A1 (en) 2025-08-21
JP7752619B2 (ja) 2025-10-10
MX2022010320A (es) 2023-01-30

Similar Documents

Publication Publication Date Title
US20250262280A1 (en) GLP-1R and GCGR Agonists, Formulations, and Methods of Use
US12257229B2 (en) Peptide pharmaceuticals for treatment of NASH and other disorders
US20240148879A1 (en) Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use
US20250134963A1 (en) Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists
WO2006000567A2 (en) Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
KR20200057059A (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
US20240269238A1 (en) Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist
US12171806B2 (en) Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
CA2666090C (en) Use of nicotinic acid adenine dinucleotide phosphate or derivative thereof as agent for treating type-2 diabetes
US20240277815A1 (en) Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist
EP4611792A1 (en) Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist
HK40101792A (en) Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists
HK40125993A (en) Therapeutic regimens and methods for reducing body weight in a subject with fatty liver disease using a glp-1r and gcgr agonist
HK40127149A (zh) 使用glp-1r和gcgr激动剂治疗心血管风险因素的治疗方案和方法
EP4741420A1 (en) Pharmaceutical composition for preventing or treating obesity comprising glp analogue as active ingredient
HK40107023A (en) Cannabidiolic acid esters for treating prader-willi syndrome